SRPT241108P100000
- 0.30
- +0.20+200.00%
Sarepta Therapeutics Newsroom
Express News | Sarepta Therapeutics Inc : Leerink Partners Cuts Target Price to $210 From $220
Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Express News | Sarepta Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results
Sarepta Therapeutics: Q3 Earnings Snapshot
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q3 Revenue $467.2M
Sarepta Therapeutics | 10-Q: Q3 2024 Earnings Report
Sarepta Therapeutics Q3 2024 Adj. EPS $0.62 Beats $(0.13) Estimate, Sales $467.172M Beat $409.297M Estimate.
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
Sarepta Therapeutics 3Q EPS 34c >SRPT
Earnings Preview: SRPT to Report Financial Results Post-market on November 06
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Business And Shares Still Trailing The Industry
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
Baird Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Optimistic Buy Rating for Sarepta Therapeutics Amid Strong International Demand and Collaborative Potential
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
S&P 500 Futures Fall In Premarket Trading; Range Resources, Mueller Industries Lead
Sarepta a New Buy at Jefferies on Muscular Dystrophy Franchise, Pipeline
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday